MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Operating Income 2011-2026 | BIO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 269 M | 338 M | 483 M | 500 M | 421 M | 230 M | -103 M | 119 M | 55.7 M | 167 M | 150 M | 169 M | 264 M | 305 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 500 M | -103 M | 241 M |
Quarterly Operating Income Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.1 M | 23.7 M | 64.5 M | 102 M | 44.6 M | 90.9 M | 89.6 M | 61.9 M | - | 94.6 M | 123 M | 146 M | - | 157 M | 125 M | 101 M | - | 110 M | 51.7 M | 74.4 M | - | 57.5 M | 56.4 M | 56.6 M | - | 36.3 M | 43.8 M | 43.6 M | 45.9 M | 38.8 M | -1.7 M | 26.2 M | -28.2 M | 22.7 M | 26.9 M | 20.2 M | - | 32.7 M | 40.2 M | 34.3 M | - | 33.2 M | 45.7 M | 20.5 M | - | 29.1 M | 52.9 M | 35.2 M | - | 65.8 M | 73.3 M | 54.4 M | - | 73.9 M | 68.2 M | 67.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 157 M | -28.2 M | 58.9 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.54 | 2.03 % | $ 685 M |  Israel |
 |
AxoGen
AXGN
|
-3.29 M | $ 32.81 | 5.67 % | $ 1.45 B | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 21.96 | 0.76 % | $ 3.14 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.47 | -2.49 % | $ 120 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.75 | -0.79 % | $ 140 M |  France |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 98.56 | 0.8 % | $ 145 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 53.03 | 0.68 % | $ 7.9 K | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 43.31 | -0.39 % | $ 1.34 B | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 126.93 | -0.69 % | $ 221 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 15.62 | 0.36 % | $ 1.24 B | Israel |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 29.03 | 2.25 % | $ 245 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 166.78 | -0.52 % | $ 12.5 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.88 | -1.53 % | $ 90.4 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 15.3 | 0.22 % | $ 414 M | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | $ 8.18 | 5.82 % | $ 180 M | Canada |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.55 | 0.03 % | $ 122 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 90.47 | -3.03 % | $ 12.3 B | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.19 | 0.85 % | $ 19.2 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 13.05 | -0.61 % | $ 1 B | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 97.9 | -0.17 % | $ 1.24 B | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 18.33 | -2.19 % | $ 423 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-50 M | $ 69.6 | 0.4 % | $ 1.96 B |  Costa-rica |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |